Dimer Health

AiME, which the company calls its AI Recovery Care Companion, does substantive work in the service: it gives patients around the clock access grounded in their medical record and care plan, and connects them to the right member of the clinical team when human clinical judgment is needed. Earlier company material described it interpreting symptoms against the patient's history, medications and comorbidities and detecting emerging risk.

What a health system or payor buys, and what the company bills for as a medical practice, is a staffed transitional care service in which a licensed Transitionist owns the episode from discharge through recovery, so the AI is the engine of the monitoring and patient contact module rather than the whole product.

The escalation target is named and accountable, and the rule that decides escalation is not published. AiME escalates to a dedicated Transitionist, a licensed clinician who owns the episode of care from discharge through recovery, rather than to a queue, and the home page promises round the clock access to the clinical care team.

The AI channel is also round the clock, and for it the company says only that AiME connects a patient to the right member of the team the moment human clinical judgment is needed. What is missing is the threshold: which symptoms or answers trigger a handoff, how quickly a clinician responds overnight, and what a patient in distress hears from AiME before a person joins.

AiME is named and its grounding is described; the technology is not. The company calls AiME proprietary clinical AI built by clinicians and grounded in physician validated protocols and in the patient's record and care plan, and its privacy policy refers to the company's own AI and machine learning models, which suggests models it trains or tunes.

Nothing says whether the conversational layer runs on a licensed foundation model, what the protocols cover, how symptom interpretation and risk detection are performed, what evaluation exists, or how a protocol or model change is tested before it reaches patients. Physician validated is a claim about how the logic was approved, not how it performs.

The architecture is described and no model provider is named. The privacy policy says information is stored and processed in the United States, that health information may improve the company's own AI and machine learning models, and that data is shared with providers, pharmacies and others working on the patient's behalf, with payment processors and with vendors that store online communications; it names Google Analytics and Meta's pixel for the website.

It links no subprocessor list and names no host or model provider, so a buyer cannot tell whether an outside language model sits between a patient's message and AiME's answer. The Healthix exchange and partner record systems receive patient information by design.

The company publishes outcome percentages with no method, denominator or source: a 42 percent reduction in readmissions, 33 percent shorter length of stay, three times the primary care follow up adherence and twice the specialist follow up adherence, and a 4.9 out of 5 patient satisfaction rating. No health system, payor, cohort, comparison group or study period is named for any of them.

Readmission reduction is the right endpoint for transitional care and a measurable one, and it is also heavily confounded by which patients are enrolled, so an unstated comparison is a material gap. The company was founded in 2023.

Dimer Health's privacy policy (current as of 13 March 2026, covering the website, the mobile app and email and text communications) states two positions a buyer can hold it to: health information may be used, in compliance with HIPAA, to improve and optimize the company's AI and machine learning models, and all information is stored and processed in the United States.

Retention is stated only generally, for as long as needed to provide the services and to meet legal obligations, and nothing says whether data is de-identified before it reaches model development or whether a patient can opt out.

The data concerned is unusual: patients recovering at home describe symptoms, worries, medication confusion and daily circumstances to AiME at any hour, often through a caregiver, and some of it is written into partner records and shared through the Healthix exchange. No safety engineering is published: nothing on guardrails for AiME's conversations or how a safety event is handled.

Dimer Health states its status as a covered entity and supports it with documents that reach the service. The home page and privacy policy (current as of 13 March 2026) say Dimer Health complies with the HIPAA Rule standards for covered entities, the privacy policy refers patients to a HIPAA Notice of Privacy Practices linked in the site footer, and a Healthix Participation Notice explains how patient information is shared through the New York exchange.

That fits a medical practice that bills Medicare, Medicaid and commercial insurance. What is not published is the position toward partner hospitals and payors: no business associate agreement, scope or subcontractor terms are stated for data received from a discharging hospital.

A development contractor's case study describes helping the company obtain a HIPAA seal of good faith; the federal government recognizes no HIPAA certification, and such a seal is a compliance firm's product rather than an audit.

A trust center hosted on Vanta is linked from the site footer, and it may list attestations that the company's other pages leave out. No SOC 2, HITRUST or ISO/IEC 27001 attestation is named on the company's own site pages, and the privacy policy describes only commercially reasonable physical, technical and administrative measures.

A development contractor's case study describes a HIPAA seal of good faith and compliant infrastructure; a seal of that kind is a compliance firm's product, not an independent examination of controls. The stakes come from the service's reach: it holds conversational health information and writes into hospital record systems, so write access to a partner's records is that partner's security question too.

No regulatory position is stated for AiME, and none is claimed. The company positions itself as a medical practice delivering transitional care, and AiME as a companion grounded in the patient's medical record and care plan that connects the patient to a clinician when human judgment is needed; earlier company material described it interpreting symptoms against the patient's history, medications and comorbidities and detecting emerging risk.

That is patient specific assessment delivered to the patient, which sits close to the boundary where device regulation applies, because the exemption for decision support depends on a health care professional reviewing the basis and a patient at home cannot. The basis is the patient's own record and care plan, and a licensed Transitionist owns the episode and receives escalations, which is what keeps this at C rather than below it.

Dimer Health describes how its AI is built and says nothing about how it is tested. The company describes AiME as proprietary, built by clinicians and grounded in physician validated protocols and in each patient's record and care plan, and its privacy policy (current as of 13 March 2026) says health information may be used to improve and optimize its AI and machine learning models in compliance with HIPAA.

No governance framework, evaluation method, escalation performance or subgroup result is published. The question that matters is escalation in the weeks after discharge, where a missed escalation can mean a readmission or worse and an unnecessary one costs clinician time, and a system tuned to reduce low acuity burden leans toward the costlier error.

Patients talk to AiME while unwell, medicated or frightened, often through a caregiver, so comprehension, language, health literacy and cognitive state after an acute illness all bear on whether a patient can describe a symptom well enough to be escalated, and patients without a caregiver lose that support.

A patient can go past the AI to a person, and nothing stands behind what the AI says. The home page promises round the clock access to the clinical care team alongside AiME, and says AiME connects patients to the right member of the team the moment human clinical judgment is needed; a licensed Transitionist owns each episode of care. That lets a patient or caregiver challenge an AiME answer by reaching a clinician.

No warranty, indemnity or remediation commitment is published, and no accuracy figure, false reassurance rate or evaluation of AiME's escalation is published. The company describes its logic as grounded in physician validated protocols, which says clinicians approved the logic at design time, not how often it escalates correctly in practice. A missed escalation after discharge means someone stays home who should have been seen, and it leaves no record unless a readmission follows.

Exchange runs through a named network in both directions. The company's Healthix Participation Notice says Dimer Health participates in the health information exchange operated by Healthix, a New York State qualified entity, uploads its patients' protected health information to it, and authorizes certain staff to access patient information through it with consent given organization by organization.

A development contractor's published case study describes the app checking for an existing record in the partner's medical record system and writing patient information into it; that is the contractor's account and names no record platform. No record system, interface standard or integration documentation is named by the company, and nothing says whether escalations and outcomes reach partner charts as structured data. Healthix covers New York, and the company operates in eight states.

The privacy policy commits a location: all information provided to Dimer Health is stored and processed in the United States. Nothing names the hosting provider, the tenancy model or how data from different partner hospitals and payors is separated, and the processing path for AiME's conversations is left open: whether an externally hosted model service processes patient messages, and on what retention terms, is not stated. The service spans a patient app, text and phone channels, writes into partner medical records and exchanges data through Healthix, so each component has its own handling.

No price is published, and how the service is paid for is discoverable. The home page says Dimer Health bills as a medical practice, delivering transitional care through the patient's existing health coverage, with insurance accepted and self pay options, and the service is offered to health systems and payors as a clinical service line.

A health system or payor cannot size its own cost from that: nothing says whether a partner pays per episode, per member or on shared savings against readmission performance, or what a self pay patient is charged.

Coverage is stated clearly and nothing validates it yet. The service is scoped to transitional care, from hospital discharge through recovery, and the home page names the states it operates in: New York, New Jersey, Pennsylvania, Ohio, North Carolina, Florida, Texas and California. Narrow, deliberate scope is a legitimate position; what is missing is validation behind it. The outcome figures the company publishes (a 42 percent readmission reduction among them) carry no cohort, comparison or partner, so no setting or condition is shown to be validated.